Welcome to our dedicated page for FutureTech II Acquisition news (Ticker: FTII), a resource for investors and traders seeking the latest updates and insights on FutureTech II Acquisition stock.
FutureTech II Acquisition Corp. (FTII) provides investors with timely updates on its strategic initiatives as a technology-focused special purpose acquisition company. This dedicated news hub aggregates official press releases, regulatory filings, and market developments related to FTII's search for merger targets in innovative tech sectors.
Access critical updates including potential acquisition announcements, capital formation progress, and leadership communications. The curated feed serves as a strategic resource for tracking this SPAC's navigation of high-growth markets like AI infrastructure, enterprise software, and disruptive digital platforms.
Discover verified information on shareholder meetings, due diligence milestones, and partnership developments. All content undergoes strict editorial review to ensure compliance with financial reporting standards while maintaining accessibility for both institutional and individual investors.
Bookmark this page for streamlined monitoring of FTII's progress in identifying merger candidates that align with its mandate of technological innovation through public market access.
FutureTech II Acquisition Corp. (NASDAQ: FTII) received a deficiency notification from Nasdaq on November 27, 2024, citing non-compliance with multiple listing requirements. The issues include: failure to file Q3 2024 Form 10-Q timely, non-compliance with Market Value of Listed Securities requirement, and falling below the minimum 1,100,000 publicly held shares requirement after 1,564,549 shares were redeemed following a November 18 special meeting.
The company is taking corrective actions by: submitting a compliance plan to Nasdaq, engaging an investment bank to increase retail distribution of securities, and working to file the Q3 10-Q by December 13, 2024. The company has requested a stay of suspension pending a Hearings Panel decision.
Longevity Biomedical and FutureTech II Acquisition Corp (NASDAQ: FTII) have announced a business combination to create a Nasdaq-listed biopharmaceutical company focused on advancing technologies for human health and longevity. The combined company will operate as Longevity Biomedical and list under the ticker symbol 'LBIO'.
Longevity Biomedical has a late-stage, diversified pipeline of therapeutic candidates across ophthalmology, cardiovascular disease, and soft tissue reconstruction. Key milestones include:
- Phase 3 start for LBI-201 (ischemic stroke)
- Phase 2 data for LBI-101 (soft-tissue reconstruction)
- Phase 2 start for LBI-001 (retinal vein occlusion)
The transaction, expected to close in Q4 2024, will provide $26.8 million from FutureTech's trust to fund clinical development. The company aims to become a leading provider of longevity-related products and services for the growing aging population.
FAQ
What is the current stock price of FutureTech II Acquisition (FTII)?
What is the market cap of FutureTech II Acquisition (FTII)?
